Synerkine Pharma, a Dutch biopharmaceutical company creating innovative pain solutions, has closed an extension of its Series A financing led by Flerie with support from new investors, InnovationQuarter and Utrecht Health Seed Fund, and existing investor Thuja Capital. The equity financing is accompanied by a matching innovation credit from Rijksdienst voor Ondernemend (RVO) Nederland – the Netherlands Enterprise Agency. The total new proceeds of EUR 12.1 million will be used to accelerate the development of Synerkine Pharma’s lead asset SK-01, a therapeutically active cytokine fusion protein, into clinical studies in complex regional pain syndrome (CRPS), a severe chronic pain indication. We advised InnovationQuarter on this investment.